Risk Factors of Lymphnode Metastasis in Patients with Thyroid Papillary Carcinoma Associated with Graves Disease.
Objective To summarize the characteristics of lymph node metastasis in patients with papillary thyroid carcinoma accompanied with Graves disease,and to provide evidence for clinical treatment. Methods Totally 98 patients with papillary thyroid carcinoma and Graves disease who had been treated in Peking Union Medical College Hospital from January 2004 to December 2013 were divided into the lymph node metastasis positive group (n=34) and lymph node metastasis negative group (n=64). The general information,blood biochemical results,pathological results,and prognoses were compared between these two groups. Results These two groups showed no significant differences in gender (χ2=0.2113,P=0.6458),age (t=1.7000,P=0.0922),tumor diameter (t=1.2559,P=0.2122),and multifocal tumors (χ2=1.9170,P=0.1661). The median level of thyrotropin receptor antibody (TR-Ab) value in the lymph node metastasis positive group was 4.84 U/L,which was significantly higher than that in the negative group which was 2.99 U/L (t=2.0169,P=0.0465). There were no significant differences in serum thyroid stimulating hormone (t=0.0257,P=0.9800),free triiodothyronine (t=1.3610,P=0.1770),free thyroxine (t=0.0082,P=0.9930),thyroid peroxidase antibody (t=0.0177,P=0.9860),and thyroglobulin antibody levels (t=1.1450,P=0.2550) between two groups. The postoperative pathological results showed that tumor capsular invasion rate (26.5% vs. 9.38%;χ2=5.006,P=0.0253) and lymph node recurrence rate (14.7% vs. 1.56%;χ2=4.583,P=0.0323) were significantly higher in the positive group than in the negative group. The distal metastasis rate in the positive group and negative group were 5.88% and 0,respectively. Conclusions There is no definite association between lymph node metastasis and tumor size in patients with thyroid papillary carcinoma associated with Graves disease. The risk factors for lymph node metastasis include TR-Ab and tumor capsular invasion,with a higher incidence of lymph nodes recurrence.
Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Yong
Y
Xie
Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Yue-Wu
YW
Liu
Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Meng-Yi
MY
Wang
Department of Pathology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Wen-Ze
WZ
Wang
Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Hong-Feng
HF
Liu
Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Xiao-Yi
XY
Li
Department of General Surgery,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Wei-Sheng
WS
Gao
D002277:Carcinoma / Q000150:complications / Q000473:pathology*; D002291:Carcinoma, Papillary; D006111:Graves Disease / Q000150:complications / Q000473:pathology*; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012307:Risk Factors; D013954:Thyroglobulin / Q000097:blood; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000150:complications / Q000473:pathology*; D013972:Thyrotropin / Q000097:blood
D013972:Thyrotropin; D013954:Thyroglobulin